Proprietary Drug PlatformA proprietary protein kinase inhibitor platform focused on oncology and neurology provides durable R&D leverage. Platform assets can produce multiple candidates, increase licensing and partnership optionality, and create long-term differentiation if clinical progress continues.

Improving Operating Cash FlowTransition to positive operating and free cash flow in 2024 indicates improving cash generation capacity. Sustained cash generation reduces immediate financing needs, supports ongoing clinical programs, and materially lengthens runway versus firms reliant solely on external funding.

Lean Cost StructureA small workforce (40 employees) suggests a lean operating model that can limit fixed overhead and conserve cash. For an R&D-focused biotech, lower structural burn improves capital efficiency and makes incremental financing requirements smaller and more manageable over time.

Bears Say

Negative Shareholders' EquityNegative shareholders' equity is a persistent solvency flag: liabilities exceed assets, impairing borrowing capacity and covenant flexibility. This structural weakness raises long-term refinancing and counterparty risk, potentially constraining growth and strategic options.

Persistent Operating LossesOngoing negative EBIT and net loss reflect structural unprofitability from operations. Continued operating deficits will necessitate repeated capital raises or partnerships, undermine retained earnings, and make it harder to finance late-stage trials or commercialization without dilution.

Reliance On Financing ActivitiesDependence on external financing to fund operations is a durable risk: access to capital can fluctuate and dilutes existing holders. Long-term reliance raises cost of capital, increases execution risk for clinical programs, and can interrupt development timelines if markets tighten.

AB Science SA News

AB Science granted U.S. patnet for masitinib in treatment of SCD

AB Science (ABSCF) announced that the United States Patent Office has formally granted a patent for methods of...

2M ago

AB Science Reports Key Developments and Financial Results

Ab Science ( ($ABSCF) ) has released its Q2 earnings. Here is a breakdown of the information Ab...

5M ago

Ab Science’s Phase 3 ALS Trial: A Key Development for Investors

Ab Science (($ABSCF)) announced an update on their ongoing clinical study. Ab Science is spearheading a pivotal Phase...

5M ago

ABSCF

AB Science Reports Reduced Deficit and Clinical Progress

Ab Science ( ($ABSCF) ) has released its Q4 earnings. Here is a breakdown of the information Ab...

10M ago

AB FAQ

What was AB Science SA’s price range in the past 12 months?

AB Science SA lowest stock price was €0.97 and its highest was €1.73 in the past 12 months.

What is AB Science SA’s market cap?

AB Science SA’s market cap is €89.48M.

When is AB Science SA’s upcoming earnings report date?

AB Science SA’s upcoming earnings report date is May 06, 2026 which is in 64 days.

How were AB Science SA’s earnings last quarter?

AB Science SA released its earnings results on Oct 10, 2025. The company reported -€0.089 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.089.

Is AB Science SA overvalued?

According to Wall Street analysts AB Science SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AB Science SA pay dividends?

AB Science SA does not currently pay dividends.

What is AB Science SA’s EPS estimate?

AB Science SA’s EPS estimate is -0.07.

How many shares outstanding does AB Science SA have?

AB Science SA has 66,184,790 shares outstanding.

What happened to AB Science SA’s price movement after its last earnings report?

AB Science SA reported an EPS of -€0.089 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.695%.

Which hedge fund is a major shareholder of AB Science SA?

Currently, no hedge funds are holding shares in FR:AB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AB Science SA

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.